Sun Liqin, Liu Jiaye, Zhao Fang, Chen Jun, Lu Hongzhou
National Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen and the Second Hospital Affiliated with the Southern University of Science and Technology, Shenzhen, Guangdong, China.
School of Public Health, Shenzhen University Health Science Center, Shenzhen, People's Republic of China, Shenzhen, Guangdong, China.
Biosci Trends. 2023 Mar 11;17(1):78-80. doi: 10.5582/bst.2023.01009. Epub 2023 Jan 22.
The tendency of the Omicron variant to rapidly became the dominant SARS-CoV-2 strain and its weaker virulence than other strains worldwide has prompted many countries to adjust their public health strategies. This work summarizes all appropriate clinical interventions to reduce the public health burden caused by COVID-19 according to guidelines from the World Health Organization and 10 countries, i.e., the United States of America (USA), India, France, Germany, Brazil, South Korea, Japan, Italy, the United Kingdom (UK), and China. Five stages of COVID-19 were identified: asymptomatic infection and mild, moderate, severe, and critical illness. Most guidelines recommend antivirals starting with mild cases for those from Germany and India. Since more drugs are being developed and are becoming available to COVID-19 patients, guidelines are increasingly being updated with new pharmacological intervention strategies. Thus, a global view needs to be adopted to provide helpful options and precise treatment strategies during the lasting fight against the COVID-19 pandemic.
奥密克戎变种迅速成为全球主要的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）毒株，且其毒力比其他毒株弱，这促使许多国家调整其公共卫生策略。这项工作根据世界卫生组织以及美国、印度、法国、德国、巴西、韩国、日本、意大利、英国和中国等10个国家的指南，总结了所有适当的临床干预措施，以减轻由2019冠状病毒病（COVID-19）造成的公共卫生负担。确定了COVID-19的五个阶段：无症状感染以及轻症、中症、重症和危重症。德国和印度的大多数指南建议，对于轻症病例应从一开始就使用抗病毒药物。由于越来越多的药物正在研发并可供COVID-19患者使用，指南越来越多地采用新的药理学干预策略进行更新。因此，在与COVID-19大流行的持久斗争中，需要采取全球视角来提供有用的选择和精确的治疗策略。
